Insmed annual ebitda margin
2009
2010
2011
2013
2018
2019
2020
2021
2022
2023
2024
2025
Insmed EBITDA Margin Growth & History (INSM)
Insmed's ebitda margin was −202.88% for fiscal 2025.
View full Insmed company overviewInsmed annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −202.88% | +35.56 pp |
| 2024 | 2024-12-31 | −238.44% | −7.74 pp |
| 2023 | 2023-12-31 | −230.70% | −46.47 pp |
| 2022 | 2022-12-31 | −184.23% | +9.97 pp |
| 2021 | 2021-12-31 | −194.20% | −38.42 pp |
| 2020 | 2020-12-31 | −155.79% | +12.79 pp |
| 2019 | 2019-12-31 | −168.57% | +2919.77 pp |
| 2018 | 2018-12-31 | −3,088.34% | — |
| 2013 | 2013-12-31 | −472.48% | — |
| 2011 | 2011-12-31 | −1,389.54% | −1273.40 pp |
| 2010 | 2010-12-31 | −116.14% | −39.33 pp |
| 2009 | 2009-12-31 | −76.81% | — |
Insmed quarterly ebitda margin
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q2.13
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.87% | +288.66 pp |
| Q1 2026 | 2026-03-31 | −48.47% | +215.47 pp |
| Q4 2025 | 2025-12-31 | −119.08% | +98.91 pp |
| Q3 2025 | 2025-09-30 | −254.32% | −28.79 pp |
| Q2 2025 | 2025-06-30 | −287.79% | +29.02 pp |
| Q1 2025 | 2025-03-31 | −263.94% | −74.99 pp |
| Q4 2024 | 2024-12-31 | −217.99% | −2.19 pp |
| Q3 2024 | 2024-09-30 | −225.54% | −42.27 pp |
| Q2 2024 | 2024-06-30 | −316.81% | −15.17 pp |
| Q1 2024 | 2024-03-31 | −188.95% | +34.39 pp |
| Q4 2023 | 2023-12-31 | −215.80% | +42.31 pp |
| Q3 2023 | 2023-09-30 | −183.27% | +2.15 pp |
| Q2 2023 | 2023-06-30 | −301.64% | −169.64 pp |
| Q1 2023 | 2023-03-31 | −223.34% | −58.98 pp |
| Q4 2022 | 2022-12-31 | −258.11% | −78.54 pp |
| Q3 2022 | 2022-09-30 | −185.42% | +28.70 pp |
| Q2 2022 | 2022-06-30 | −132.01% | +55.18 pp |
| Q1 2022 | 2022-03-31 | −164.35% | +35.03 pp |
| Q4 2021 | 2021-12-31 | −179.56% | +52.26 pp |
| Q3 2021 | 2021-09-30 | −214.12% | −93.41 pp |
| Q2 2021 | 2021-06-30 | −187.18% | −68.12 pp |
| Q1 2021 | 2021-03-31 | −199.39% | −45.18 pp |
| Q4 2020 | 2020-12-31 | −231.83% | −124.90 pp |
| Q3 2020 | 2020-09-30 | −120.71% | +18.77 pp |
| Q2 2020 | 2020-06-30 | −119.07% | +80.26 pp |
| Q1 2020 | 2020-03-31 | −154.21% | +152.57 pp |
| Q4 2019 | 2019-12-31 | −106.93% | +775.37 pp |
| Q3 2019 | 2019-09-30 | −139.48% | — |
| Q2 2019 | 2019-06-30 | −199.33% | — |
| Q1 2019 | 2019-03-31 | −306.78% | — |
| Q4 2018 | 2018-12-31 | −882.30% | — |
| Q2 2013 | 2013-06-30 | −70.56% | — |
| Q4 2011 | 2011-12-31 | −624.45% | — |
| Q3 2011 | 2011-09-30 | −8,018.62% | −7985.53 pp |
| Q2 2011 | 2011-06-30 | −1,062.78% | — |
| Q1 2011 | 2011-03-31 | −458.46% | — |
| Q3 2010 | 2010-09-30 | −33.09% | — |
Insmed ebitda margin trends
Over the last five fiscal years, Insmed's ebitda margin decreased from −155.79% to −202.88%, a change of −47.10 percentage points. The latest reported quarter, Q2 2026, shows 0.87%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Insmed source filings ↗Community posts
Insmed raises sales floors as Brinsupri revenue reaches $400 million
Insmed ($INSM) reported third-quarter 2026 revenue of $524.4 million, with Brinsupri contributing $400.1 million, up 29% from the preceding quarter. Arikayce sales increased 9% from a year earlier to $124.4 million, helped by international ...
